Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
D000225:Adenine / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D052176:Azulenes; D020137:Base Pair Mismatch; D001569:Benzodiazepines / Q000494:pharmacology*; D002455:Cell Division; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D004249:DNA Damage; D004260:DNA Repair; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005838:Genotype; D006147:Guanine / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D008956:Models, Chemical; D009243:NAD; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D000077204:Temozolomide
C479234:1-(4-dimethylaminomethylphenyl)-8,9-dihydro-7H-2,7,9a-benzo(cd)azulen-6-one; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D052176:Azulenes; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D009243:NAD; D001569:Benzodiazepines; D006147:Guanine; C008450:7-methylguanine; D003606:Dacarbazine; D000225:Adenine; D002945:Cisplatin; D000077204:Temozolomide